Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YH003 + pembrolizumab + nab-paclitaxel in unresectable/metastatic mucosal melanoma
CTR20221066Phase 2Completed
- Sponsor
- Youhe Medical Technology
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of ciltistotug in mucosal melanoma (MM), sponsored by Youhe Medical Technology. Started Jun 2022; status: completed.
02
Drugs
ciltistotug
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on CTR20221066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20221066.